CMTM5 (Gene)

Organism:

Homo sapiens

Synonyms:CKLF like MARVEL transmembrane domain containing 5, CKLFSF5, CMTM5, ENTREZ:116173, HGNC:19176, MIM:607888, NM_001037288, NM_001288744, NM_001288745, NM_001288746, NM_138460, NM_181618, NP_001032365, NP_001275673, NP_001275674, NP_001275675, NP_612469, XM_024449465, XM_024449466, XM_024449467, XP_024305233, XP_024305234, XP_024305235

Id:ENSG00000166091

Entrez:116173

Ensembl:ENSG00000166091

Description:CKLF like MARVEL transmembrane domain containing 5

This gene encodes a member of the chemokine-like factor superfamily. This family of genes encodes multi-pass membrane proteins that are similar to both the chemokine and the transmembrane 4 superfamilies of signaling molecules. The encoded protein may exhibit tumor suppressor activity. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2014]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View CMTM5's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with CMTM5.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using CMTM5.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for CMTM5.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with CMTM5.

Results found

Linked to

	Label	Description
	GSE261563 CX-5461 6 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE158431 2 V 0 PIOGLITAZONE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE214931 temozolomide 4 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE97352 1 V 2 DASATINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE165071,GSE165072 1 V 0 DEXAMETHASONE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE176008 pyridoxine 7 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE214931 4 V 0 TEMOZOLOMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE137702 2 V 1 SELINEXOR HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE261563 CX-5461 3 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE159678 hydroxychloroquine 6 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS

GSE261563 CX-5461 6 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE158431 2 V 0 PIOGLITAZONE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE214931 temozolomide 4 v 0 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE97352 1 V 2 DASATINIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE165071,GSE165072 1 V 0 DEXAMETHASONE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE176008 pyridoxine 7 v 3 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE214931 4 V 0 TEMOZOLOMIDE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE137702 2 V 1 SELINEXOR HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE261563 CX-5461 3 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE159678 hydroxychloroquine 6 v 7 human up

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.